A recently published article serves as a call for research to be conducted to discover how cannabis could impact the management of bipolar disorder (BD). Presented in the article is a full review of the advantages and disadvantages of cannabis-based medicine in the treatment of BD and provides insight into possible mechanisms might affect the pathophysiology of the disorder. The insights listed within the article provide the rationale for examining the endocannabinoid system, specifically the cannabinoid receptor 2, with the hopes of finding therapeutic targets for mood control associated with BD.
Scientists offer a strong counter-position to the belief that cannabis causes psychosis, pointing out the difference between correlation and causation. They argue that smoke exposure from any source (including cigarettes) could explain the reported link between cannabis and psychosis.
Dronabinol-Induced Hypomania: A Case Report and Literature Review
An HIV patient who also suffers from bipolar disorder was administered dronabinol, a synthetic cannabis alternative. Following a dosage increase, the previously stable patient presented to his psychiatrist in a state of hypomania. Although this singular case study cannot be used to make any definitive conclusion, it underscores the need for further research surrounding the effects of cannabis on mood